PPARGC1A and osteoporosis: Huang et al. [217] showed that nicotinamide mononucleotide attenuated glucocorticoid-induced osteogenesis inhibition by modulating the SIRT1/PGC-1α signaling pathway, further highlighting the therapeutic potential of SIRT1 activators in glucocorticoid-induced osteoporosis.